Opus Genetics, Inc. reported $9.9M of revenue over the trailing twelve months, −36% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $9.9M (to Q2 2026). Net income: −$108M, trailing twelve months to Q2 2026. Operating margin: −854%, trailing twelve months to Q2 2026. EPS: −$1.35, trailing twelve months to Q2 2026.

IRDOpus Genetics, Inc.

Healthcare

$4.45+119% 1Y

$4.45

$1.7452 weeks$6.09

IRD as reported

Opus Genetics, Inc. reported $9.9M of revenue over the trailing twelve months, −36% on the year before. 9 reported series are charted on this page, each one as filed.

$9.9M

Revenue, trailing twelve months · to Q2 2026 · −36% against the twelve months before

Net income: −$108M
Net income · +85% year on year · trailing twelve months to Q2 2026
Operating margin: −854%
Operating margin · trailing twelve months to Q2 2026
EPS: −$1.35
EPS · −30% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for IRD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$9.9M	−36%	Q2 2026
Net income	−$108M	+85%	Q2 2026
EPS	−$1.35	−30%	Q2 2026
Operating margin	−854%	n/a	Q2 2026
Net margin	−1276%	n/a	Q2 2026
ROE	−101%	n/a	Q2 2026
ROA	−141%	n/a	Q2 2026
ROIC	104%	n/a	Q2 2026
Free cash flow	−$3.6M	n/a	Q4 2019 · 26 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.